ROVI has published the financial results recorded in the first quarter of 2022. Among the main indicators obtained, the following stand out:
- Operating revenue increased by 57% to 205.6 million euros driven by (i) the strength of the contract manufacturing organization (“CMO”) business, which grew by 167%, and (ii) the specialty pharmaceutical business, where sales rose 16%.
- EBITDA increased by 113% to 74.3 million euros and Net profit increased by 123% to 53.0 million euros.
- Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins) increased by 19% to 75.9 million euros.
- Sales of prescription-based pharmaceutical products rose 17% to 100.5 million euros in the first quarter of 2022.
- Sales of the enoxaparin biosimilar increased 50% to 44.2 million euros in the first quarter of 2022 mainly because of (i) the launch of the product in four new countries in the first quarter of 2022 and (ii) the increase in the demand for the product in countries where we are already present.
- In April, Okedi® (Risperidone ISM®) was launched in Germany for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
ROVI is in a new phase of growth, supported by the strength of the third-party manufacturing business and the pharmaceutical specialties business, and exptects its operating revenue to increase by between 15% and 20% for 2022.